Peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy queues
A new peer-reviewed publication in the prestigious Helicobacter journal (2026) confirms the clinical utility of the GastroPanel® test as a non-invasive triage tool for gastric cancer risk stratification.
GastroPanel® combines a biomarker-based test with risk algorithms, enabling safe prioritization of patients for endoscopy and reducing unnecessary procedures. In a practical implementation in Chile (Molina), the method led to an 87% reduction in endoscopy queues and ensured rapid access to endoscopy for high- and medium-risk patients.
“This is a very significant milestone for Biohit and healthcare systems worldwide,” says Jussi Hahtela, CEO of Biohit Oyj. “We now have peer-reviewed evidence that endoscopy queues can be reduced by up to 87% without compromising patient safety. The scarcity of healthcare resources is a global challenge, and GastroPanel® offers a practical, evidence-based solution for more efficient resource allocation and improving early detection of gastric cancer.”
The results strengthen the position of the GastroPanel® test as a scalable and evidence-based solution for promoting early detection of gastric cancer and for more efficient allocation of healthcare resources worldwide.
12 Likes